Literature DB >> 18797837

[Rational imaging in locally advanced prostate cancer].

M Beissert1, R Lorenz, E W Gerharz.   

Abstract

Prostate cancer is one of the principal medical problems facing the male population in developed countries with an increasing need for sophisticated imaging techniques and risk-adapted treatment options. This article presents an overview of the current imaging procedures in the diagnosis of locally advanced prostate cancer. Apart from conventional gray-scale transrectal ultrasound (TRUS) as the most frequently used primary imaging modality we describe computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). CT and MRI not only allow assessment of prostate anatomy but also a specific evaluation of the pelvic region. Color-coded and contrast-enhanced ultrasound, real-time elastography, dynamic contrast enhancement in MR imaging, diffusion imaging, and MR spectroscopy may lead to a clinically relevant improvement in the diagnosis of prostate cancer. While bone scintigraphy with (99m)Tc-bisphosphonates is still the method of choice in the evaluation of bone metastasis, whole-body MRI and PET using (18)F-NaF, (18)F-FDG, (11)C-choline, (11)C-acetate, and (18)F-choline as tracers achieve higher sensitivities.

Entities:  

Mesh:

Year:  2008        PMID: 18797837     DOI: 10.1007/s00120-008-1720-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  38 in total

1.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.

Authors:  E Ackerstaff; B R Pflug; J B Nelson; Z M Bhujwalla
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  Fluorine-18: a new isotope for bone scanning.

Authors:  M BLAU; W NAGLER; M A BENDER
Journal:  J Nucl Med       Date:  1962-07       Impact factor: 10.057

3.  SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients.

Authors:  Wolfgang Römer; Anton Nömayr; Michael Uder; Werner Bautz; Torsten Kuwert
Journal:  J Nucl Med       Date:  2006-07       Impact factor: 10.057

Review 4.  [MRI for troubleshooting detection of prostate cancer].

Authors:  D Beyersdorff; B Hamm
Journal:  Rofo       Date:  2005-06

5.  Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome.

Authors:  R H Liebross; A Pollack; S P Lankford; G K Zagars; A C von Eschenbach; F B Geara
Journal:  Cancer       Date:  1999-04-01       Impact factor: 6.860

6.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

7.  Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial.

Authors:  J A Smith; P T Scardino; M I Resnick; A D Hernandez; S C Rose; M J Egger
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

8.  The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

9.  The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.

Authors:  I Igerc; S Kohlfürst; H J Gallowitsch; S Matschnig; E Kresnik; I Gomez-Segovia; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-11       Impact factor: 9.236

10.  Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.

Authors:  W J Ellis; M P Chetner; S D Preston; M K Brawer
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  3 in total

1.  Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.

Authors:  Cristina Nanni; Riccardo Schiavina; Stefano Boschi; Valentina Ambrosini; Cinzia Pettinato; Eugenio Brunocilla; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-17       Impact factor: 9.236

2.  MRl of prostate cancer antigen expression for diagnosis and immunotherapy.

Authors:  Jing Ren; Fang Wang; Guangquan Wei; Yong Yang; Ying Liu; Mengqi Wei; Yi Huan; Andrew C Larson; Zhuoli Zhang
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 3.  Tracking Transplanted Stem Cells Using Magnetic Resonance Imaging and the Nanoparticle Labeling Method in Urology.

Authors:  Jae Heon Kim; Hong J Lee; Yun Seob Song
Journal:  Biomed Res Int       Date:  2015-08-27       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.